These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
226 related articles for article (PubMed ID: 19917618)
21. [Safety of methotrexate in rheumatoid arthritis: a retrospective cohort study in clinical practice]. La Montagna G; Tirri R; Vitello R; Malesci D; Buono R; Mennillo G; Valentini G Reumatismo; 2006; 58(4):261-7. PubMed ID: 17216014 [TBL] [Abstract][Full Text] [Related]
22. Persistence With Conventional Triple Therapy Versus a Tumor Necrosis Factor Inhibitor and Methotrexate in US Veterans With Rheumatoid Arthritis. Sauer BC; Teng CC; Tang D; Leng J; Curtis JR; Mikuls TR; Harrison DJ; Cannon GW Arthritis Care Res (Hoboken); 2017 Mar; 69(3):313-322. PubMed ID: 27273801 [TBL] [Abstract][Full Text] [Related]
23. Certolizumab pegol in combination with dose-optimised methotrexate in DMARD-naïve patients with early, active rheumatoid arthritis with poor prognostic factors: 1-year results from C-EARLY, a randomised, double-blind, placebo-controlled phase III study. Emery P; Bingham CO; Burmester GR; Bykerk VP; Furst DE; Mariette X; van der Heijde D; van Vollenhoven R; Arendt C; Mountian I; Purcaru O; Tatla D; VanLunen B; Weinblatt ME Ann Rheum Dis; 2017 Jan; 76(1):96-104. PubMed ID: 27165179 [TBL] [Abstract][Full Text] [Related]
24. Drug survival, efficacy and toxicity of monotherapy with a fully human anti-tumour necrosis factor-alpha antibody compared with methotrexate in long-standing rheumatoid arthritis. Barrera P; van der Maas A; van Ede AE; Kiemeney BA; Laan RF; van de Putte LB; van Riel PL Rheumatology (Oxford); 2002 Apr; 41(4):430-9. PubMed ID: 11961174 [TBL] [Abstract][Full Text] [Related]
25. Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study. Weisman MH; Moreland LW; Furst DE; Weinblatt ME; Keystone EC; Paulus HE; Teoh LS; Velagapudi RB; Noertersheuser PA; Granneman GR; Fischkoff SA; Chartash EK Clin Ther; 2003 Jun; 25(6):1700-21. PubMed ID: 12860493 [TBL] [Abstract][Full Text] [Related]
26. Infliximab for the treatment of rheumatoid arthritis. Blumenauer B; Judd M; Wells G; Burls A; Cranney A; Hochberg M; Tugwell P Cochrane Database Syst Rev; 2002; 2002(3):CD003785. PubMed ID: 12137712 [TBL] [Abstract][Full Text] [Related]
28. Treatment strategies in patients with rheumatoid arthritis for whom methotrexate monotherapy has failed: data from the NOR-DMARD register. Lie E; van der Heijde D; Uhlig T; Mikkelsen K; Kalstad S; Kaufmann C; Rødevand E; Kvien TK Ann Rheum Dis; 2011 Dec; 70(12):2103-10. PubMed ID: 21875874 [TBL] [Abstract][Full Text] [Related]
29. Evaluation of two strategies (initial methotrexate monotherapy vs its combination with adalimumab) in management of early active rheumatoid arthritis: data from the GUEPARD trial. Soubrier M; Puéchal X; Sibilia J; Mariette X; Meyer O; Combe B; Flipo RM; Mulleman D; Berenbaum F; Zarnitsky C; Schaeverbeke T; Fardellone P; Dougados M Rheumatology (Oxford); 2009 Nov; 48(11):1429-34. PubMed ID: 19741011 [TBL] [Abstract][Full Text] [Related]
30. Alternative tumour necrosis factor inhibitors (TNFi) or abatacept or rituximab following failure of initial TNFi in rheumatoid arthritis: the SWITCH RCT. Brown S; Everett CC; Naraghi K; Davies C; Dawkins B; Hulme C; McCabe C; Pavitt S; Emery P; Sharples L; Buch MH Health Technol Assess; 2018 Jun; 22(34):1-280. PubMed ID: 29900829 [TBL] [Abstract][Full Text] [Related]
31. Abatacept with methotrexate versus other biologic agents in treatment of patients with active rheumatoid arthritis despite methotrexate: a network meta-analysis. Guyot P; Taylor P; Christensen R; Pericleous L; Poncet C; Lebmeier M; Drost P; Bergman G Arthritis Res Ther; 2011; 13(6):R204. PubMed ID: 22151924 [TBL] [Abstract][Full Text] [Related]
32. Testing treat-to-target outcomes with initial methotrexate monotherapy compared with initial tumour necrosis factor inhibitor (adalimumab) plus methotrexate in early rheumatoid arthritis. Kavanaugh A; van Vollenhoven RF; Fleischmann R; Emery P; Sainsbury I; Florentinus S; Chen S; Guérette B; Kupper H; Smolen JS Ann Rheum Dis; 2018 Feb; 77(2):289-292. PubMed ID: 29146743 [TBL] [Abstract][Full Text] [Related]
33. Cost utility of tumour necrosis factor-α inhibitors for rheumatoid arthritis: an application of Bayesian methods for evidence synthesis in a Markov model. Nguyen CM; Bounthavong M; Mendes MA; Christopher ML; Tran JN; Kazerooni R; Morreale AP Pharmacoeconomics; 2012 Jul; 30(7):575-93. PubMed ID: 22640174 [TBL] [Abstract][Full Text] [Related]
34. Less radiographic progression with adalimumab plus methotrexate versus methotrexate monotherapy across the spectrum of clinical response in early rheumatoid arthritis. Emery P; Genovese MC; van Vollenhoven R; Sharp JT; Patra K; Sasso EH J Rheumatol; 2009 Jul; 36(7):1429-41. PubMed ID: 19369462 [TBL] [Abstract][Full Text] [Related]
35. The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Breedveld FC; Weisman MH; Kavanaugh AF; Cohen SB; Pavelka K; van Vollenhoven R; Sharp J; Perez JL; Spencer-Green GT Arthritis Rheum; 2006 Jan; 54(1):26-37. PubMed ID: 16385520 [TBL] [Abstract][Full Text] [Related]
36. Longterm effect of delaying combination therapy with tumor necrosis factor inhibitor in patients with aggressive early rheumatoid arthritis: 10-year efficacy and safety of adalimumab from the randomized controlled PREMIER trial with open-label extension. Keystone EC; Breedveld FC; van der Heijde D; Landewé R; Florentinus S; Arulmani U; Liu S; Kupper H; Kavanaugh A J Rheumatol; 2014 Jan; 41(1):5-14. PubMed ID: 24241487 [TBL] [Abstract][Full Text] [Related]
37. Elevated liver enzyme tests among patients with rheumatoid arthritis or psoriatic arthritis treated with methotrexate and/or leflunomide. Curtis JR; Beukelman T; Onofrei A; Cassell S; Greenberg JD; Kavanaugh A; Reed G; Strand V; Kremer JM Ann Rheum Dis; 2010 Jan; 69(1):43-7. PubMed ID: 19147616 [TBL] [Abstract][Full Text] [Related]
38. A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: the treatment of Early Aggressive Rheumatoid Arthritis Trial. Moreland LW; O'Dell JR; Paulus HE; Curtis JR; Bathon JM; St Clair EW; Bridges SL; Zhang J; McVie T; Howard G; van der Heijde D; Cofield SS; Arthritis Rheum; 2012 Sep; 64(9):2824-35. PubMed ID: 22508468 [TBL] [Abstract][Full Text] [Related]
39. Predictors of treatment initiation with tumor necrosis factor-α inhibitors in patients with rheumatoid arthritis. Desai RJ; Rao JK; Hansen RA; Fang G; Maciejewski ML; Farley JF J Manag Care Spec Pharm; 2014 Nov; 20(11):1110-20. PubMed ID: 25351972 [TBL] [Abstract][Full Text] [Related]
40. Meta-Regression of a Dose-Response Relationship of Methotrexate in Mono- and Combination Therapy in Disease-Modifying Antirheumatic Drug-Naive Early Rheumatoid Arthritis Patients. Bergstra SA; Allaart CF; Stijnen T; Landewé RBM Arthritis Care Res (Hoboken); 2017 Oct; 69(10):1473-1483. PubMed ID: 27992656 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]